Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial

Simple item page
dc.contributor.authorNakanjako, Damalie
dc.contributor.authorSsinabulya, Isaac
dc.contributor.authorNabatanzi, Rose
dc.contributor.authorBayigga, Lois
dc.contributor.authorKiragga, Agnes
dc.contributor.authorJoloba, Moses
dc.contributor.authorKaleebu, Pontiano
dc.contributor.authorKambugu, Andrew D.
dc.contributor.authorKamya, Moses R.
dc.contributor.authorSekaly, Rafick
dc.contributor.authorElliott, Alison
dc.contributor.authorMayanja-Kizza, Harriet
dc.date.accessioned2022-05-25T12:20:39Z
dc.date.available2022-05-25T12:20:39Z
dc.date.issued2015
dc.description.abstractT-cell activation independently predicts mortality, poor immune recovery and non-AIDS illnesses during combination antiretroviral therapy (cART). Atorvastatin showed anti-immune activation effects among HIV-infected cART-naïve individuals. We investigated whether adjunct atorvastatin therapy reduces T-cell activation among cART-treated adults with suboptimal immune recovery.A randomised double-blind placebo-controlled crossover trial, of atorvastatin 80 mg daily vs. placebo for 12 weeks, was conducted among individuals with CD4 increase <295 cells/μl after seven years of suppressive cART. Change in T-cell activation (CD3 + CD4 + /CD8 + CD38 + HLADR+) and in T-cell exhaustion (CD3 + CD4 + /CD8 + PD1 + ) was measured using flow cytometry.Thirty patients were randomised, 15 to each arm. Atorvastatin resulted in a 28% greater reduction in CD4 T-cell activation (60% reduction) than placebo (32% reduction); P = 0.001. Atorvastatin also resulted in a 35% greater reduction in CD8-T-cell activation than placebo (49% vs. 14%, P = 0.0009), CD4 T-cell exhaustion (27% vs. 17% in placebo), P = 0.001 and CD8 T-cell exhaustion (27% vs. 16%), P = 0.004. There was no carry-over/period effect. Expected adverse events were comparable in both groups, and no serious adverse events were reported.Atorvastatin reduced T-cell immune activation and exhaustion among cART-treated adults in a Ugandan cohort. Atorvastatin adjunct therapy should be explored as a strategy to improve HIV treatment outcomes among people living with HIV in sub-Saharan Africa.en_US
dc.identifier.citationNakanjako, D., Ssinabulya, I., Nabatanzi, R., Bayigga, L., Kiragga, A., Joloba, M., ... & Mayanja‐Kizza, H. (2015). Atorvastatin reduces T‐cell activation and exhaustion among HIV‐infected c ART‐treated suboptimal immune responders in U ganda: a randomised crossover placebo‐controlled trial. Tropical medicine & international health, 20(3), 380-390.https://doi.org/10.1111/tmi.12442en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3332
dc.language.isoenen_US
dc.publisherTropical medicine & international healthen_US
dc.subjectatorvastatin, HIV/AIDS, antiretroviral therapy, adjunct therapy, immune activation, immune recoveryen_US
dc.titleAtorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda a randomised crossover placebo-controlled trial.pdf
Size:
446.36 KB
Format:
Adobe Portable Document Format
Description:
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences